Share on LinkedInShare on LinkedIn

ARTICLE · 06 JULY 2010

Competition Law and Intellectual Property Go Another Round

Mayer Brown
Mayer Brown
Contributor
Mayer Brown

Mayer Brown

Mayer Brown is a leading international law firm positioned to represent the world’s major...

View firm profile
Explore more from Mayer Brown

In a new judgment that further explores the application of competition law to intellectual property rights, the EU General Court has upheld a 2005 Commission decision finding that AstraZeneca abused a market-dominant position by blocking or delaying the entry of generic versions of its ulcer drug Losec.

European UnionAntitrust/Competition Law

Article by Gillian Sproul , Nathalie Jalabert-Doury , Kiran S. Desai and Jens Peter Schmidt

Originally published 2 July 2010

Keywords: competition law, intellectual property rights, AstraZeneca, abuse of market dominance, Losec, patent, EU Treaty, misleading representations,

In a new judgment that further explores the application of competition law to intellectual property rights, the EU General Court has upheld a 2005 Commission decision finding that AstraZeneca1 abused a market-dominant position by blocking or delaying the entry of generic versions of its ulcer drug Losec2. However, the Court has also reduced to €52.5 million the €60 million fine originally imposed on AstraZeneca, reflecting the Commission's failure to prove one element of its case.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from